Alcobra Ltd. to Present at Two CNS Focused Conferences in April

TEL AVIV, Israel, April 6, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that corporate presentations will be provided at two conferences focused on Central Nervous System (CNS) disorders in April.

10th Annual Neurotech Investing & Partnering Conference
Date: Tuesday, April 7
Time: 3:30pm Pacific Time
Location: Hotel Nikko, San Francisco
Presenter: David Baker, Chief Commercial Officer
Conference Information:
Neurology Innovation Conference
Date: Sunday, April 19
Time: 3:30pm Eastern Time
Location: Embassy Suites, Washington DC
Presenter: Jonathan Rubin, MD, MBA, Chief Medical Officer
Conference Information:

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and in Fragile X Syndrome. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.